4.178EUR-4.61%Mkt Cap: 97.21M EURP/E: —Last update: 2026-06-01
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Ph…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap97.21M EUR
Enterprise Value83.38M EUR
Revenue (TTM)1.78M EUR
Gross Profit1.78M EUR
Net Income (TTM)37.45M EUR
Revenue/Share0.0810 EUR
Last Price4.178 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2024
Employees64
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0012127173
Valuation
P/E (Trailing)—
P/E (Forward)-3.96
PEG—
EV/EBITDA-2.83
EV/Revenue46.79
P/S57.19
P/B2.87
EPS (TTM)-1.69
EPS (Forward)-1.11
52W Range
2.87227% of range7.700
52W High7.700 EUR
52W Low2.872 EUR
Profitability
Gross Margin100.00%
Oper. Margin-2272.16%
EBITDA Margin0.00%
Profit Margin53.59%
ROE58.68%
ROA30.21%
Growth
Revenue Growth-0.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF48.44M EUR
CapEx (TTM)77.00K EUR
FCF Margin-937.63%
FCF Yield-17.19%
Net Debt-12.98M EUR
Net Debt/EBITDA0.44
Balance Sheet
Debt/Equity0.72
Current Ratio1.54
Quick Ratio1.19
Book Value/Sh1.524 EUR
Cash/Share2.687 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)14.07 EUR
Target Range8.200 EUR – 21.00 EUR
# Analysts3
Ownership
Shares Out.23.27M
Float15.90M
Insiders27.19%
Institutions2.71%
Technical
SMA 503.801 (+9.9%)
SMA 2004.929 (-15.2%)
Beta0.79
S&P 52W Chg27.94%
Avg Vol (30d)374.52K
Avg Vol (10d)381.93K
Technical Indicators
RSI (14)48.7
MACD0.2816
MACD Signal0.3540
MACD Hist.-0.0723
BB Upper5.715 EUR
BB Middle4.612 EUR
BB Lower3.508 EUR
BB Width47.87%
ATR (14)0.4396 EUR
Vol Ratio (20d)1.43x